Operant, Oral Alcoholic Beer Self-administration by C57BL/6J Mice: Effect of BHF177, a Positive Allosteric Modulator of GABA(B) Receptors
Overview
Affiliations
Rationale: With its high palatability, near-beer has been successfully used in rats as a vehicle to induce ethanol oral self-administration.
Objectives: The study aimed to develop an operant model of oral alcoholic beer self-administration promoting a stable intake of pharmacologically relevant amounts of ethanol in free-feeding C57BL/6J mice. It also aimed to assess the model's predictive validity by evaluating the influence of baclofen, a GABA(B) agonist, and BHF177, a GABA(B) positive allosteric modulator, on alcoholic beer self-administration.
Methods: Mice were trained to self-administer, under a fixed ratio three schedule of reinforcement, 10 μl of beer containing increasing ethanol concentrations (0-18% v/v) in daily 30-min sessions. The effects on motor coordination (rotarod), locomotor activity (open field, automated cages) and anxiety-like behavior (elevated plus maze, EPM) were examined. Baclofen (1.25-5 mg/kg, intraperitoneal, i.p.) and BHF177 (3.75-30 mg/kg, i.p.) were used to see the effects on 9% alcoholic beer and near-beer self-administration.
Results: Near-beer stably maintained operant oral self-administration in mice. Adding ethanol to near-beer reduced the number of active lever presses, while the corresponding amount of ethanol self-administration increased (0.8-1.0 g/kg/session). Motor impairment was observed when more than 1.3 g/kg/session of ethanol was self-administered with beer and slight but consistent hyperlocomotion with more than 0.9-1.0 g/kg/session. BHF177 (15 mg/kg) preferentially reduced 9% alcoholic beer self-administration, while the higher dose (30 mg/kg)-like baclofen 5 mg/kg-also reduced near-beer self-administration.
Conclusions: The operant model of oral alcoholic beer self-administration in C57BL/6J mice should prove useful for studying ethanol-reinforced behaviors and to identify candidate compounds for the pharmacological management of alcohol addiction.
Liu B, Guan F, Zhao J, Niu Y, Jiang H Oxid Med Cell Longev. 2022; 2022:4661519.
PMID: 36439691 PMC: 9691330. DOI: 10.1155/2022/4661519.
GABA Receptors and Alcohol Use Disorders: Preclinical Studies.
Holtyn A, Weerts E Curr Top Behav Neurosci. 2020; 52:157-194.
PMID: 32808090 DOI: 10.1007/7854_2020_178.
Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.
Viudez-Martinez A, Garcia-Gutierrez M, Fraguas-Sanchez A, Torres-Suarez A, Manzanares J Br J Pharmacol. 2018; 175(16):3369-3378.
PMID: 29859012 PMC: 6057893. DOI: 10.1111/bph.14380.
Brolese G, Lunardi P, de Souza D, Lopes F, Leite M, Goncalves C PLoS One. 2015; 10(5):e0127845.
PMID: 25978644 PMC: 4433332. DOI: 10.1371/journal.pone.0127845.
GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence.
Agabio R, Colombo G Front Neurosci. 2014; 8:140.
PMID: 24936171 PMC: 4047789. DOI: 10.3389/fnins.2014.00140.